Johnson & Johnson (NYSE: JNJ) announced today that 11 abstracts featuring new data on its robust portfolio and pipeline in neuropsychiatry will be presented at the 64th Annual Meeting of the American ...
Key market opportunities in the Bipolar Disorder market include developing targeted treatments for bipolar depression due to current unmet needs, capitalizing on late-stage pipeline products projected ...
The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback